Systemic lupus erythematosus (SLE). Systemic lupus erythematosus (SLE)
Conditions
Sponsors
Bojnourd University of Medical Sciences
Eligibility
Sex/Gender
All
Age
20 Years to 55 Years
Inclusion criteria
Inclusion criteria: Men and women with mild to moderate systemic lupus erythematosus based on Systemic Lupus Erythematosus Disease Activity Index score
Exclusion criteria
Exclusion criteria: The patient did not receive antibacterial medication at the time of the studyPatients with lupus and no underlying disease such as kidney transplant who receive immunosuppressive drugs other than systemic lupus erythematosus for any reason.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Interleukin 10. Timepoint: In this study, blood is taken from the patient before starting the treatment, and then treatment with probiotics is started. Probiotic treatment is done for two months, and then blood is taken from the patient once again and interleukin 10 is measured. Method of measurement: ELISA.;Transforming Growth Factor-ß. Timepoint: In this study, blood is taken from the patient before starting the treatment, and then treatment with probiotics is started. Probiotic treatment is done for two months, and then blood is taken from the patient once again and TGF-b is measured. Method of measurement: ELISA.;Systemic Lupus Erythematosus Disease Activity Index (SLEDAI). Timepoint: In this study, before the start of the treatment, blood is taken from the patient and the SLE disease activity indedx (SLAEDAI) questionnaire is completed, and then the treatment with pobiotics is started, probiotic treatment is carried out for two months, and then the SLEDAI questionnaire is completed once again. Method of measurement: Questionnaire SELDAI K2000. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactBojnourd University of Medical Sciences
Bojnourd University of Medical Sciences
Outcome results
None listed